BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 24659820)

  • 21. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
    Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
    Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor.
    Mooney SM; Parsana P; Hernandez JR; Liu X; Verdone JE; Torga G; Harberg CA; Pienta KJ
    J Cell Biochem; 2015 Jan; 116(1):115-23. PubMed ID: 25160502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate Cancer Growth and Migration.
    Eguchi T; Csizmadia E; Kawai H; Sheta M; Yoshida K; Prince TL; Wegiel B; Calderwood SK
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
    Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
    Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
    Rodgers JJ; McClure R; Epis MR; Cohen RJ; Leedman PJ; Harvey JM; ; Thomas MA; Bentel JM
    J Cell Biochem; 2019 Jan; 120(1):848-860. PubMed ID: 30161276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
    O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
    Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
    Beltran H; Wyatt AW; Chedgy EC; Donoghue A; Annala M; Warner EW; Beja K; Sigouros M; Mo F; Fazli L; Collins CC; Eastham J; Morris M; Taplin ME; Sboner A; Halabi S; Gleave ME
    Clin Cancer Res; 2017 Nov; 23(22):6802-6811. PubMed ID: 28842510
    [No Abstract]   [Full Text] [Related]  

  • 33. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
    Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
    PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
    Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
    Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced
    Kitz J; Lefebvre C; Carlos J; Lowes LE; Allan AL
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1
    Qian J; Shen S; Chen W; Chen N
    Biomed Res Int; 2018; 2018():4174232. PubMed ID: 29568752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SET8 induces epithelial‑mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1.
    Hou L; Li Q; Yu Y; Li M; Zhang D
    Mol Med Rep; 2016 Feb; 13(2):1681-8. PubMed ID: 26717907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.
    Bucay N; Bhagirath D; Sekhon K; Yang T; Fukuhara S; Majid S; Shahryari V; Tabatabai Z; Greene KL; Hashimoto Y; Shiina M; Yamamura S; Tanaka Y; Deng G; Dahiya R; Saini S
    Cell Death Differ; 2017 Jul; 24(7):1263-1274. PubMed ID: 28498363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.